Paradigm Health has raised $78 million in an oversubscribed Series B round as the U.S. technology company accelerates its effort to embed clinical trials directly within routine patient care across the country and abroad.
The investment was led by ARCH Venture Partners, joined by new backer DFJ Growth and returning investors including F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, and the American Cancer Society’s BrightEdge Fund, several of which increased their positions in the company.
The funding aims to expand Paradigm Health’s footprint as global drugmakers seek faster, more cost-efficient trials and major healthcare providers look to bring research closer to patients’ day-to-day care environments. The company currently supports Phase I–III oncology studies for 15 of the world’s 20 largest pharmaceutical companies.
“When trials run more efficiently, new treatments reach patients sooner,” said Robert Nelsen, Managing Partner at ARCH Venture Partners and Co-Founder and Board Chair of Paradigm Health. “The industry has needed a unified platform for years—one that helps hospitals and sponsors run studies faster, more intelligently, and at lower cost.”
The announcement comes months after Paradigm Health acquired the clinical research business of Flatiron Health, giving the company what is now considered the largest oncology research network in the U.S. That network spans 45 states, 166 healthcare organizations, and 2,100 care locations, placing roughly 70% of U.S. cancer patients within accessible distance of an active clinical trial site.
Chief Executive Officer Kent Thoelke said the company is focused on solving the longstanding divide between academic research hubs and the community clinics where most patients receive care.
“Only a small fraction of trials occur outside major academic centers,” Thoelke said. “Patients in community and rural areas deserve equal access. We’re creating a scalable research ecosystem that functions inside real clinical workflows, reducing the burden on providers and speeding enrollment dramatically.”
The company’s AI-powered infrastructure automates tasks such as patient-trial matching and site feasibility assessments, enabling health systems to enroll participants up to four times faster while lowering operational demands. Its newly launched Trial Design Service further supports pharmaceutical sponsors in building interventional and pragmatic studies within everyday care settings.
Justin Kao, Partner at DFJ Growth, described Paradigm Health as “the AI-native platform built for this moment,” adding that the surge in AI-driven drug discovery will require more efficient trial operations. “They pair breakthrough technology with the country’s largest clinical network to make trials dramatically faster and more accessible,” he said.
Editorial Analysis: Why Paradigm Health’s Model Matters
Paradigm Health is positioning itself at the intersection of two forces reshaping drug development: the explosion of AI-enabled therapeutics and the growing demand for real-world, decentralized research. While much of the industry talks about democratizing clinical trials, few organizations have successfully paired advanced data automation with national-scale clinical infrastructure. Paradigm appears to be one of the first doing both at once.
By integrating trials directly into routine care, the company addresses several long-standing inefficiencies—not just slow recruitment, but also the lack of diversity and geographic inclusion in research. Its reach into community oncology clinics is particularly significant, as these sites treat the majority of U.S. cancer patients yet remain historically underrepresented in clinical studies.
Moreover, the expansion beyond oncology into neuroscience, cardiology, and metabolic disease suggests a strategic recognition that the next wave of therapeutics—including gene therapies, precision drugs, and AI-discovered candidates—will require broader and more agile trial networks. If Paradigm continues executing at this scale, it may help modernize not only trial logistics but the entire ecosystem’s expectations for speed, equity, and scientific rigor.
The company’s trajectory aligns with global healthcare trends: decentralization, real-time data use, and community-based medicine. If sustained, its model could materially reduce the time it takes for novel therapies to move from lab benches to patients’ hands—one of the most consequential bottlenecks in modern medicine.
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com
